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Abstract
Clostridium difﬁcile infections (CDIs) are a common cause of antibiotic-associated diarrhoea and associated with CDI-related mortality in c.
10%. To date, there is no prediction model in use that guides clinicians to identify patients at high risk for complicated CDI. From 2006
to 2009, nine Dutch hospitals included hospitalized CDI patients in a prospective cohort. Potential predictors of a complicated course
(ICU admission, colectomy or death due to CDI) were evaluated in uni- and multivariate logistic regression. A score was constructed
that was internally validated by bootstrapping. Furthermore, a pilot external validation was performed. Twelve per cent of 395 CDI
patients had a complicated course within 30 days after diagnosis. Age (≥85 years, OR 4.96; 50–84 years, 1.83), admission due to
diarrhoea (OR 3.27), diagnosis at the ICU department (OR 7.03), recent abdominal surgery (OR 0.23) and hypotension (OR 3.25) were
independent predictors of a complicated course. These variables were used to construct a prediction model. A score subsequently
classiﬁed patients into high risk (39% with a complicated course), intermediate (16%), low (5%) or virtually no risk of experiencing a
complicated course. The score performed well after internal validation (AUC 0.78) and a pilot external validation among 139 patients
showed similar good performance (AUC 0.73). We present an easy-to-use, clinically useful risk score that is capable of categorizing
CDI patients according to their outcome. Because classiﬁcation is available at diagnosis, it could have major implications for treatment
choice.
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Introduction
Clostridium difﬁcile infection (CDI) commonly presents as a
colitis, which occurs when toxin is produced by the bacterium.
Symptoms may include cramps, fever, abdominal pain or signs
of an ileus or peritonitis; diarrhoea is almost always present.
Inﬂammation of the gut may be so severe that hypotension,
perforation or a toxic megacolon occurs [1,2]. The number of
patients that die as a consequence of CDI increased when a
virulent C. difﬁcile strain, PCR ribotype 027, emerged in 2002.
CDI is now found to increase the absolute risk of death within
30 days by c. 10% [3,4].
Vancomycin and metronidazole are currently the most
frequently used drugs to treat CDI, but newer treatment
options, such as the recently licensed drug ﬁdaxomicin, are now
available [5]. This drug has been shown to be as effective as
vancomycin in the treatment of CDI, but the population that
beneﬁts most from this new but costly treatment remains to be
determined. In patients with severe CDI, vancomycin treatment
is superior to metronidazole [6,7]. Because severe symptoms
are associated with a complicated course (e.g. death), it is
important to identify patients at risk of a complicated course and
use this as a guide towards treatment [2,8]. In an attempt to
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characterize patients who die due to CDI, several risk factors
have been described, including advanced age, concomitant use of
antibiotics, fever, admission to the intensive care unit and
presence of leucocytosis, elevated creatinine or low serum
albumin [6,9–14]. Furthermore, C. difﬁcile-speciﬁc factors such
as PCR ribotype have been associated withmortality due toCDI
[10]. In spite of the detection of useful predictors of a
complicated course, no clinically useful prediction model has
been constructed to date [15].
In this study, we aim to deﬁne prognostic markers for a
complicated course of CDI, using variables that are available at
a patient’s bedside at time of diagnosis. Next, we aimed to
develop an easy-to-use prediction rule that could help




From March 2006 to May 2009, nine Dutch hospitals (ﬁve
academic and four community) prospectively included
hospitalized patients with CDI in a cohort study. Hospitals
participated for a minimum of six consecutive months in the
3-year study period. Patients from all departments and
co-morbidities were considered eligible. CDI was deﬁned as
the presence of diarrhoea (≥3 unformed stools per 24-h
period) and a positive C. difﬁcile toxin test. In addition to
testing because the treating physician suspected CDI, all
patients with diarrhoea who were hospitalized for 2 or more
days were routinely tested for C. difﬁcile. The toxin test that
was used differed per hospital according to the local standard.
Four hospitals used the ImmunoCard Toxins A&B (Meridian
Bioscience, Cincinnati, OH, USA), three used a cytotoxicity
assay, one used the Premier Toxins A&B (Meridian) and
another hospital used the VIDAS C. difﬁcile A&B test (bio-
Merieux, Marcy-l’Etoile, France). For every patient, only a
single inclusion in the study was possible. The study was
approved by the Institutional Review Ethics Boards.
Data collection
Patient information was collected by a study physician (AG)
and registered on a standardized questionnaire, using patient
records, the electronic medical information system and by
consulting the physician in charge. Demographic characteristics
such as age, sex, hospital and department of diagnosis were
collected. Information on risk factors for CDI present in the
3 months prior to the onset of diarrhoea was collected and
included previous medication (antibiotics, immunosuppressive
agents, chemotherapeutic agents, antacids and proton-pump
inhibitors) and hospital admissions. Data concerning underlying
medical conditions were classiﬁed using the 10th edition of the
International Classiﬁcation of Diseases and the Charlson’s
Co-morbidity Index [16]. At the day of diagnosis (plus or
minus 1 day), signs and symptoms during physical examination
were recorded: fever (temperature >38.5°C), macroscopic
blood in the stool, hypotension (systolic blood pressure below
100 mmHg and/or diastolic blood pressure below 60 mmHg)
and abdominal pain. Serum creatinine was recorded before the
onset of diarrhoea.
Variables had missing data in <3% of patients, except for
fever, hypotension and bloody diarrhoea, which were
incomplete in 10–13%. Creatinine values were not registered
in one hospital (13%). To account for missing data in
multivariable analysis, values were imputed using multiple
imputation. This method is appropriate when values are
missing at random (MAR) [17], which seemed reasonable to
assume in our study because variables that were predictive of
the missing data were determined. All potential predictors, the
outcome variable and nine additional variables were included
in the imputation procedure.
Submission of C. difﬁcile isolates to the LUMC was
requested from all participants; however, one hospital
submitted no samples and two others submitted only a few
(<1/3). Submitted isolates were cultured on selective plates for
C. difﬁcile after an alcohol shock and identiﬁed as C. difﬁcile by
the detection of the gluD gene by PCR. All positive isolates
were PCR-ribotyped as previously described [18,19].
Outcome measurement
Thirty days after diagnosis the course of CDI was considered by
consensus of the treating physician and a study physician (MH or
AG). A complicated course was deﬁned according to interna-
tional recommendations [20,21]: (i) death as a direct or indirect
consequence of CDI, (ii) (prolonged) admission to the intensive
care unit due to CDI, (iii) colectomy due to CDI. Survival status
of all patients was checked using the Dutch Civil Registration
System in which all Dutch inhabitants are registered.
Predictors of a complicated course of CDI
Based on previous research we selected potential predictors
of a complicated course of CDI that could be obtained at time
of diagnosis, including age, department of diagnosis, use of
antibiotic agents, Charlson’s Co-morbidity Index and
creatinine count [3,10–12,22,23]. Additionally, we selected
sex, hospital of diagnosis (academic or community), location of
onset of diarrhoea (healthcare or community), reason for
admission (diarrhoea or other), some well-known risk factors
for acquiring CDI (medication and interventions) and signs and
symptoms that were recorded during physical examination as
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potential predictors, with the exception of abdominal pain,
which was deemed too subjective. Potential predictors were
analysed using univariate logistic regression analysis.
Multivariable logistic regression was performed for all potential
predictors with a p-value <0.50 in univariate analysis.
Subsequently, the model was reduced by stepwise excluding
variables with a p-value of >0.10 based on the log likelihood
ratio test (backward selection). Therefore, the strongest
predictors remained in the ﬁnal model. Results were displayed
as odds ratios (ORs).
Prediction rule development, performance and internal
validation
Any prognostic model shows a too optimistic performance in
the dataset from which it is developed (over-ﬁtting) [24]. To
adjust for this optimism and to validate the model, we used
bootstrapping techniques. During this process, the model is
constructed numerous times (n = 200) using a subset of the
dataset to predict the outcome of the other part of the
dataset. This way, the optimism can be quantiﬁed with a
number (shrinkage factor). The regression coefﬁcients of the
ﬁnal model were multiplied with the shrinkage factor and
subsequently rounded to integers to construct a simple
prediction rule. For each patient we calculated a summed
score. The discriminative ability of our model was expressed
by calculation of the area under the receiver operating
characteristic curve (ROC area), which ranges from no
discrimination (0.5) to perfect discrimination (1.0). Calibration
of the original model was evaluated by using the Hosmer and
Lemeshow test. A simpliﬁed version of the prognostic rule was
constructed to divide patients into low, medium and high-risk
categories. Similarly, this simpliﬁed rule was tested for its
discriminative ability, sensitivity and speciﬁcity. Furthermore,
performance was assessed by calculating the positive and
negative predictive values and diagnostic accuracy.
Sensitivity analyses and pilot external validation
Several sensitivity analyses were performed, including (i)
restriction to patients aged ≥15 years, (ii) restriction to
patients who were treated for CDI with metronidazole and
(iii) a complete case analysis. A small cohort (n = 139) was
used as a pilot of external validation. This cohort consisted of
all CDI patients diagnosed between May 2009 and May 2011 in
a single hospital (Radboud University Medical Center,
Nijmegen, the Netherlands). This hospital also participated in
the derivation study between 2006 and 2009; deﬁnitions of
CDI and outcome were equal to those used to construct the
prediction rule.
Analyses were carried out using PASW Statistics version
17.0 (SPSS Inc., Chicago, Illinois, USA) and R version 2.12.2,
package Design and pROC (The R Foundation for Statistical
Computing, Vienna, Austria).
Results
In total, 395 patients with CDI were included. Their median age
was 65 years (IQR 52–77); 55.7% of the population was male.
Three months prior to the onset of diarrhoea, 85.0% had used
antibiotic therapy and 54.7% had been admitted to a healthcare
facility. Abdominal pain (54%), fever (60%) and hypotension
(30%) were frequently present at the time of diagnosis, whereas
bloody diarrhoea (15%) was present in a minority of the
patients. Patient characteristics are displayed in Table 1.
Within the ﬁrst 30 days after diagnosis, 88.2% of the
patients received antibiotic treatment for CDI. Most fre-
quently, metronidazole was used (74.3%). A combination of
metronidazole and vancomycin was used in 11.3% and
vancomycin monotherapy in 2.6%. Sixty-ﬁve patients (16.5%)
died within 30 days after the diagnosis; 38 (9.9%) of these
deaths were related to CDI. Five patients had a colectomy and
three were admitted to the intensive care unit due to CDI;
therefore, a complicated course due to CDI was observed in
46 patients (11.9%).
The PCR ribotype causing CDI was known for 207 of the
225 samples (92.0%) that were submitted for typing (52.4% of
all patients); the most frequently found types were 014
(16.9%), 078 (12.1%), 001 (8.7%) and 027 (8.2%). As described
in detail elsewhere [25], type 027 was associated with the
highest 30-day mortality risk (29%).
Prediction rule
Seventeen variables were selected as potential predictors and
included in univariate analysis (Table 1). Age, department of
diagnosis, admission to an academic hospital, recent abdominal
surgery, the prior use of antibiotic agents, diarrhoea as a reason
for admission and hypotension were signiﬁcantly associatedwith
a complicated course of CDI after 30 days in this analysis. Sex,
prior use of cytostatic or immunosuppressive agents, bloody
diarrhoea and Charlson’s Co-morbidity index, were discarded
after univariate analysis due to a p-value of >0.50. The remaining
12 variables were included in multivariable logistic regression.
After reduction of the model by backward selection, ﬁve
variables remained strongly associated with a complicated
course of CDI: age (OR 4.96 for age ≥85 years; OR 1.83 for
age 50–84 years), department of diagnosis (OR 0.98 for surgery;
OR 7.03 for the ICU department), recent abdominal surgery
(OR 0.23), hypotension (OR 3.25) and admission because of
diarrhoea (OR3.27;Table 2).Calibrationof thismodelwas good
(Hosmer Lemeshow test p = 0.36 in the original dataset). The
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regression coefﬁcients of these variables weremultiplied by 0.86
(shrinkage factor), after which theywere converted into a score.
For each patient the total score was calculated, ranging between
3 and 10. All 395 patients were stratiﬁed according to their
summed score in Table 3. No patients had a summed score of
>8. The observed probability of developing a complicated course
due toCDIwas calculated for each stratum,which showed that a
high score correlated with a high risk of development of a
complicated course of CDI and vise versa (Table 3).
Based on these results, four risk categories were deﬁned: no
risk (<0 points), low risk (0–1 points), medium risk (2–3 points)
and a high risk (≥4 points) of developing a complicated course of
CDI. A patient that is categorized in the highest group has c. 40%
chance of developing a complicated course, whereas a patient
categorized in the lowest group has virtually no chance of
developing a complicated course due to CDI. After internal
validation of the model, the ROC area was 0.80 (0.73–0.86) for
the complete and 0.78 (0.71–0.85) for the simpliﬁed risk score.
TABLE 1. Univariate analysis of potential predictors for the development of a complicated course due to CDI
CDI patients
(n = 395)




n % n % n %
Demographic characteristics
Age
<49 years 85 22 6 13 79 23 1 (reference) 0.01
50–84 years 275 70 31 67 237 70 1.72 (0.69–4.28)
>85 years 35 9 9 20 23 7 5.15 (1.66–16.0)
Male sex 220 56 24 52 191 56 0.85 (0.46–1.57) 0.59
Academic hospital 266 67 23 50 239 71 0.42 (0.22–0.78) 0.01
Department of diagnosis
Other departments 293 74 35 76 251 74 1 (reference) <0.01
Surgery 83 21 4 9 78 23 0.37 (0.13–1.07)
Intensive Care Unit 19 5 7 15 10 3 5.02 (1.80–14.0)
Medication and intervention historyb
Cytostatic agents 64 16 7 15 55 16 0.91 (0.39–2.15) 0.84
Immunosuppressive agents 172 44 21 47 146 44 1.13 (0.60–2.10) 0.71
Proton pump inhibitors 251 64 34 76 211 63 1.82 (0.89–3.71) 0.10
Recent abdominal surgery 110 28 4 9 105 31 0.21 (0.07–0.59) <0.01
Recent admission 210 55 28 61 177 54 1.37 (0.71–2.49) 0.38
Antibiotic agents 335 85 34 74 293 87 0.44 (0.21–0.90) 0.03
Clinical characteristics
Charlson Index
0 59 15 7 15 52 15 1 (reference) 0.53
1–2 150 38 14 30 134 40 0.78 (0.30–2.03)
3–4 120 31 15 33 101 30 1.10 (0.42–2.87)
>5 64 16 10 22 50 15 1.49 (0.53–4.21)
Diarrhoea as reason for admission 104 27 23 50 78 23 3.31 (1.76–6.22) <0.01
Healthcare onset diarrhoea 283 72 28 61 248 74 0.55 (0.29–1.04) 0.06
Fever 208 60 25 66 174 59 1.36 (0.67–2.76) 0.40
Hypotension 117 30 25 63 88 30 3.86 (1.94–7.68) <0.01
Bloody diarrhoea (macroscopic) 52 15 7 16 44 15 1.14 (0.48–2.71) 0.77
Laboratory parameter
Creatinine count prior to start of diarrhoea
<90 199 58 17 43 178 61 1 (reference) 0.05
>90 109 32 16 40 89 30 1.88 (0.91–3.90)
Dialysis 33 10 7 18 25 9 2.93 (1.11–7.77)
aOutcome is missing for 10 patients (2.5%), therefore the maximum number of patients is 46 with a severe course and 339 without a severe course.
bMedication and intervention history was gathered from the 3 months prior to the start of diarrhoea.








≤49 years 1 (reference) Reference 0.00 0.00 0
50–84 years 1.83 (0.68–4.97) 0.24 0.61 0.52 1
≥85 years 4.96 (1.40–17.6) 0.01 1.60 1.38 3
Department of diagnosis
Other departments 1 (reference) Reference 0.00 0.00 0
Surgery 0.98 (0.30–3.17) 0.97 0.02 0.02 0
Intensive Care Unit 7.03 (2.02–24.4) <0.01 1.95 1.68 3
Recent abdominal surgery 0.23 (0.07–0.73) 0.01 1.47 1.26 3
Hypotension 3.25 (1.53–6.91) <0.01 1.18 1.01 2
Diarrhoea as reason for admission 3.27 (1.57–6.80) <0.01 1.18 1.01 2
These predictors, selected in multivariable analyses, were included in the ﬁnal model. Their regression coefﬁcients were shrunk in order to correct for optimism and subsequently
a score was developed. The chance that an individual patient develops a complicated course due to CDI can be predicted by the following formula: p = 1/(1 + exp-
(3.15 + 0.52 9 age 50–84 + 1.38 9 age ≥85  0.02 9 department of surgery + 1.68 9 department of ICU  1.26 9 recent abdominal surgery + 1.01 9 hypoten-
sion + 1.01 9 diarrhoea as a reason for admission)).
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Using our prediction rule, several cut-off points can be used
to deﬁne patients as ‘at risk of a complicated course’.
Sensitivity and speciﬁcity were 84% and 61%, respectively,
for a cut-off point of ≥2, which changed to 43% and 90% for a
cut-off point of ≥4. Performance of the prediction rule using
different cut-off points is displayed in Table 4.
Sensitivity analyses and pilot external validation
We performed sensitivity analyses on two different patient
selections: patients treated with metronidazole only and
patients aged ≥15 years old (95% of the original cohort).
Furthermore, we performed a complete case analysis in which
260 patients (66%) were eligible for multivariable analysis and
326 patients (83%) had complete data for the ﬁnal prediction
rule. All analyses yielded the same strongest ﬁve predictors of
a complicated course due to CDI: diarrhoea as a reason for
admission, department of diagnosis, age, recent abdominal
surgery and hypotension; identical to the predictors selected in
the original analysis. Furthermore, similar ROC areas were
found (≥0.77 in both selected patient groups and the complete
case analysis).
A pilot for external validation was performed in a cohort of
139 patients. Seven of these patients (5.0%) developed a
complicated course of CDI within 30 days after diagnosis.
Although numbers were limited, a higher score corresponded
with a higher chance of a complicated course: patients with
score <0 (n = 18) had a 0% chance of experiencing a
complicated course, score 0–1 (n = 55) had a 4% chance,
score 2–3 (n = 52) had a 4% chance, and score ≥4 had a 21%
chance (n = 14). The risk score also performed relatively well,
with an AUC of 0.73 and a sensitivity and speciﬁcity of 43% and
92%, respectively, at a cut-off point of ≥4.
Discussion
In the literature, C. difﬁcile infections are associated with high
mortality risks of around 10% in the ﬁrst 30 days [3,4]. In our
study, the CDI-related mortality was also 10%, and 12% of the
CDI patients experienced a complicated course within 30 days
after diagnosis. A complicated course was associated with
advanced age, admission because of diarrhoea and diagnosis in
the ICU department. Furthermore, recent abdominal surgery
(negative predictor) and hypotension were independent pre-
dictors of a complicated course. Here, we present a multivar-
iable risk score for a complicated course of CDI, composed of
these factors, which are easily accessible at diagnosis. The
score can distinguish patients with a high risk (39%) of
developing a complicated course from those who have an
intermediate risk (16%), low risk (5%) or virtually no risk of
developing a complicated course.
Several studies previously attempted to construct predic-
tion rules and classify patients according to their outcome.
However, none of these rules reached clinical practice due to
small sample sizes and the lack of internal or external
validation [15]. Two of 13 published prediction rules on the
outcome of CDI were validated, however, the inclusion of
subjective parameters (altered mental status) and parameters
that are not available at diagnosis (radiologic ﬁndings) limited
their use [26–29]. A validated risk score using recurrences as
an outcome does exist [30], though its value is questioned
because it was constructed with <50 patients in the derivation
and validation cohorts. Our prediction rule is internally








<0 63 0% –2 40 01 7 0
0 65 3 0–1 156 5% (2–9%)
1 92 7
2 26 11 2–3 121 17% (10–23%)
3 95 18
4 7 34





TABLE 4. Performance of the simpliﬁed risk score, using
three different cut-off points to deﬁne a complicated course
Cut-off point for a complicated course
≥0 ≥2 ≥4
NPV 1 0.96 0.92
PPV 0.15 0.24 0.39
Sensitivity 1 0.84 0.43
Speciﬁcity 0.18 0.61 0.90
Accuracy 0.28 0.64 0.84
NPV, negative predictive value; PPV, positive predictive value.
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validated and based on simple, clinical parameters that are
available after completion of history and physical examination.
This enables the physician to use it at a patient’s bedside and
on time for treatment guidance.
The prediction rule we present here is capable of deﬁning a
high-risk population: the positive predictive value rises from
12% (prevalence of a complicated course in the CDI popula-
tion) to 39% when a cut-off of ≥4 is used. This high-risk
population is in strong need of treatment options other than
metronidazole and might beneﬁt most from novel but
expensive treatments. Current evidence favours vancomycin
above metronidazole in patients with severe symptoms of CDI
[6]; therefore, it is likely that the high-risk group beneﬁts from
vancomycin. Overall, our prediction rule could guide more
diverse treatment modalities; however, the exact threshold
(e.g. cut-off of ≥4 or ≥2) for a treatment other than
metronidazole should be determined based on careful consid-
eration regarding the harms vs. the beneﬁts of the treatment.
It should be emphasized that the majority of our patients were
treated, including those with approximately no chance of
developing a complicated course. This prediction rule there-
fore does not recommend watchful waiting in patients with a
low risk of experiencing a complicated course.
Advanced age has frequently been associated with mortality
and a complicated courseofCDI [11,31–35].Diagnosis in the ICU
department [36] and hypotension [33,36–38] have also been
associated with a complicated course in previous research. A
quarter of the patients in our study were admitted because of
diarrhoea, which was associated with a complicated course after
30 days. Morrison et al. [35] found a similar percentage and
association in their large cohort of 485 patients and hypothesized
that this could be due to a more complicated course of
community-acquired infections. In our population, however,
63% of the patients whowere admitted because of diarrhoea had
been admitted to a healthcare facility in the preceding 3 months
and therefore did not have community-acquired infection. We
hypothesize that admission due to diarrhoea is a proxy for
patients with severe symptoms and consequently at risk of a
complicated course. Patients with recent abdominal surgery less
frequently experienceda complicated course inour study. Several
studies report this [11,32,39] and the explanation of Bhangu et al.
[32] is that these patients are probably often younger and ﬁtter
compared with patients without recent surgery. This explanation
seems reasonable; however, in our study the mean age (59.5 vs.
61.9 years) and Charlson’s Co-morbidity Index (category of ≥5,
14.5% vs. 17.3%) only slightly differ between patients with vs.
without previous surgery. Therefore, other yet unknown factors
probably contribute to the difference between patients with and
without recent abdominal surgery.
Serum creatinine was related to a complicated course in
univariate analysis; however, it was discarded after
multivariable analysis. Other laboratory parameters, such as
a hypoalbuminaemia and leucocytosis, were in our study not
measured at diagnosis but during the course of the disease.
We recently concluded that timing of these measurement
highly inﬂuences the usefulness of these laboratory predictors
[40]. For this reason, these potential predictors were not
included in our analysis. Rapid subtyping of C. difﬁcile is
unavailable in most laboratories and typing data are not
available at diagnosis. The presence of a hypervirulent strain
such as PCR ribotype 027 was therefore not evaluated as a
potential predictor in our analysis.
Although our prediction rule is constructed using strong
methodology and is based on a clinically relevant outcome, our
study has several limitations. First of all, the measurement of
outcome is based on clinical judgement, which can be subjective.
To minimize ascertainment bias, outcome was based on the
consensus of two physicians and death within 30 days was
veriﬁed by using the highly reliable Dutch National Registration
System. Additionally, we used tests with different sensitivities
and speciﬁcities to construct our cohort, which could have
inﬂuenced our study population, and therefore themortality risk
(more sensitive testswere associatedwith a highermortality risk
in our study; data not shown). However, as many hospitals still
use ‘insensitive’ enzyme immunoassays in the Netherlands, our
study is likely to represent the mortality among CDI patients in
Dutchhospitals [CID].Althoughourmodel performedwell after
internal validation (AUC 0.78) and a small external validation, its
generalizability should be tested again in a setting with different
researchers, locations and time. Interestingly, in our derivation
and pilot-validation cohorts, the frequency of a complicated
course differed (12% and 5%, respectively). Pilot-validation was
carried out in a single centre that also had a better survival during
the derivation period (when8%of the patients had a complicated
course), which explains the difference.
In summary, we present a multivariable risk score that is
designed to identify patients who are at risk of a complicated
course of CDI. Because these patients might beneﬁt from a
different treatment, classiﬁcation of patients according to their
outcome could have major implications. Guidance of
treatment decisions and selection of high-risk patients as a
target population for new, but expensive, treatments may be
one of the future applications [5]. Additionally, the populations
of different trials can now be compared and our score enables
surveillances to more objectively classify patients at risk of a
complicated course of CDI. External validation and determi-
nation of the clinical threshold for initiating the complicated
course treatment are aims for further research.
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